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157Statin use and lower extremity amputation risk in
nonelderly diabetic patients
Min-Woong Sohn, PhD,a,b Judith L. Meadows, MD,c Elissa H. Oh, MA,b
Elly Budiman-Mak, MD, MPH,a,d Todd A. Lee, PharmD, PhD,a,e Neil J. Stone, MD,c and
William B. Pearce, MD,f Hines, Chicago, and Maywood, Ill
Objective: To examine the association between use of statin and nonstatin cholesterol-lowering medications and risk of
nontraumatic major lower extremity amputations (LEAs) and treatment failure (LEA or death).
Methods: A retrospective cohort of patients with Type I and Type 2 diabetes mellitus (diabetes) was followed for 5 years
between 2004 and 2008. The follow-up exposure duration was divided into 90-day periods. Use of cholesterol-lowering
agents, diabetic medications, hemoglobin A1c, body mass index, and systolic and diastolic blood pressures were observed
in each period. Demographic factors were observed at baseline. Major risk factors of LEA including peripheral
neuropathy, peripheral artery disease, and foot ulcers were observed at baseline and were updated for each period. LEA
and deaths were assessed in each period and their hazard ratios (HRs) were estimated. The study took place in the U.S.
Department of Veterans Affairs Healthcare system, and the subjects consisted of cholesterol drug-naïve patients with
Type I or II diabetes who were treated in the U.S. Department of Veterans Affairs Healthcare system in 2003 and
were <65 years old at the end of follow-up.
Results: Of 83,953 patients in the study cohort, 217 (0.3%) patients experienced a major LEA and 11,716 (14.0%)
patients experienced an LEA or death (treatment failure) after a mean follow-up of 4.6 years. Compared with patients
who did not use cholesterol-lowering agents, statin users were 35% to 43% less likely to experience an LEA (HR, 0.65;
95% conﬁdence interval [CI], 0.42-0.99) and a treatment failure (HR, 0.57; 95% CI, 0.54-0.60). Users of other
cholesterol-lowering medications were not signiﬁcantly different in LEA risk (HR, 0.95; 95% CI, 0.35-2.60) but had
a 41% lower risk of treatment failure (HR, 0.59; 95% CI, 0.51-0.68).
Conclusions: This is the ﬁrst study to report a signiﬁcant association between statin use and diminished amputation risk
among patients with diabetes. In this nonrandomized cohort, beneﬁcial effects of statin therapy were similar to that seen
in large-scale clinical trial experience. For LEA risk, those given nonstatins did not have a statistically signiﬁcant beneﬁt
and its effect on LEA risk was much smaller compared with statins. Unanswered questions to be explored in future studies
include a comparison of statins of moderate vs high potency in those with high risk of coronary heart disease and an
exploration of whether the effects seen in this study are simply effects of cholesterol-lowering or possibly pleiotropic
effects. (J Vasc Surg 2013;58:1578-85.)Diabetes elevates the risk of limb loss, adverse cardio-
vascular events, and death.1 Aggressive management of
dyslipidemia is a cornerstone of risk-factor modiﬁcation in
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8guidelines deﬁne diabetes as a coronary heart disease risk
equivalent and mandate a low-density lipoprotein choles-
terol (LDL-C) goal of <100 mg/dL for all individuals
with diabetes3 and an optional goal of LDL-C <70
mg/dL for very high-risk individuals.2
While there is trial evidence that LDL-C-lowering
therapy reduces cardiovascular risk in patients with dia-
betes, its effect on vascular health has not been clearly eval-
uated.4 The landmark Heart Protection Study, which
included 5963 patients with diabetes, demonstrated a sig-
niﬁcant 22% reduction in cardiovascular events and revas-
cularizations among subjects with diabetes randomized to
simvastatin 40 mg but failed to show a signiﬁcant reduction
in lower extremity amputations (LEAs).4 The Cholesterol
Treatment Trialists evaluated 18,686 individuals with
diabetes from 14 randomized trials of statin therapy.5
Although there was a signiﬁcant reduction in vascular
mortality in patients assigned to statins, the association
between LEA and statin use was not reported.
Given the current lack of evidence on the effect of sta-
tins on amputation risk, our large nontrial population of
individuals in the VA healthcare system with diabetes
provides a unique opportunity to evaluate the association
of statin and nonstatin cholesterol-lowering medication
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follow-up. Our objective was to examine how cholesterol-
lowering medications among new users are associated with
5-year amputation risk and amputation-free survival.
METHODS
Research design. We used a retrospective cohort
comprised of nonelderly (<65 years of age) diabetic
patients who were not using cholesterol-lowering medica-
tions at baseline. We used inpatient and outpatient data
sets for ﬁscal years 2002 and 2003 (October 2001 to
September 2003; all years in this study are ﬁscal years) to
identify patients who were treated for diabetes in the U.S.
Department of Veterans Affairs (VA) healthcare system. An
annual inpatient data set contains patient records for all
hospitalizations that occurred during each ﬁscal year in all
VA medical centers across the country. For each hospital
stay, patient conditions using up to 10 International
Classiﬁcation of Diseases, Ninth Revision (ICD-9) diag-
nostic codes and all procedures performed are recorded
using ICD-9 procedure codes. The outpatient data set
contains “encounter” level data for all visits to VA hospital-
based and community-based outpatient clinics each year.
An encounter is a patient seen at a “clinic stop,” a concept
analogous to a revenue center in the private sector. A
patient can have several encounters during an outpatient
care visit. Each encounter contains up to 10 patient diag-
noses in ICD-9 codes and up to 20 procedures in Current
Procedural Technology, Version 4 codes.
We identiﬁed an individual as having diabetes if he or
she had a prescription of diabetes medication in 2003
and/or two or more inpatient or outpatient care episodes
with a diagnosis of diabetes (detected by an ICD-9-CM
diagnostic code 250.xx) in 2002 to 2003.6
Because VA beneﬁciaries may also be entitled to receive
health care from Medicare providers, we limited our study
cohort to those aged <65 years at the end of follow-up
(September 30, 2008) so that they would not be eligible
for Medicare beneﬁts on account of age before the end
of follow-up. At the time of this study, we did not have
access to Medicare data, and diagnoses made by Medicare
providers were not observable in this study.
We additionally excluded all patients who died before
October 1, 2004 (the index date from when the follow-
up started), who had a history of any LEA before the index
date, and who were new users of, or new enrollees in, the
VA healthcare system in 2003. New users and/or new
enrollees were excluded because baseline comorbidities
were not observable.
Identiﬁcation of amputation and mortality. The
goal of treatment for patients with diabetic complications
in the lower extremities is amputation-free survival. As
our main outcomes, we used LEA and treatment failure
deﬁned as an LEA or death. We identiﬁed all major (ankle
or above) LEAs between 2004 and 2008 by searching both
inpatient and outpatient data. The procedure codes in
the ICD-9-CM or CPT used to identify LEAs are shown in
the Supplementary Table I (online only). Deaths wereidentiﬁed by the VA Vital Status ﬁle, which contains deaths
for the VA beneﬁciaries up to April 2009. Any death before
the end of follow-up was identiﬁed as a competing risk for
amputation and as an event for the treatment failure. The
VA Vital Status ﬁle has over 98% sensitivity and 97%
speciﬁcity compared with the National Death Index.7
Cholesterol-lowering medications. We divided the
5-year follow-up into 90-day periods and observed
cholesterol-lowering medications used during each period.
A 90-day period was chosen because a large number of
prescriptions for diabetic medications are ﬁlled for 90 days
in the VA. The VA pharmacy prescription-level data were
searched to identify all cholesterol-lowering agents dis-
pensed to patients during each period. Medications were
grouped according to their drug classes into statins (sim-
vastatin, atorvastatin, ﬂuvastatin, lovastatin, pravastatin,
and rosuvastatin), ﬁbrates (bezaﬁbrate, ciproﬁbrate, cloﬁ-
brate, gemﬁbrozil, and fenoﬁbrate), nicotinic acid (niacin),
bile acid sequestrants (cholestyramine, colesevelam, and
colestipol), and cholesterol absorption inhibitors (ezeti-
mibe). Days of supply ﬁlled for each class of medications
were separately tallied from the dispensing date, and over-
supply for a period was rolled over to the next. We deﬁned
a patient as a user of a class of medications if the patient had
at least 30 days’ supply of medications in the same class
during each period. We likewise identiﬁed patients who
had at least 30-day supply of any cholesterol-lowering
medication in 2003 and excluded them from the study
cohort.
Potential confounders. Other risk factors of LEA and
death were identiﬁed either at baseline or during each
period from various sources that may potentially confound
the association between cholesterol-lowering medication
use and outcome. Demographic factors, including patient
age, gender, race/ethnicity, marital status, and coexisting
conditions, were obtained from inpatient and outpatient
records in 2003. We identiﬁed some coexisting conditions
in 2003 for which statins may be contraindicated and their
new diagnoses during each period.
Other major risk factors of LEA or mortality include
coronary artery disease (CAD), peripheral artery disease
(PAD), peripheral neuropathy, foot ulcers, osteomyelitis,
and history of vascular procedures. These were detected
by ICD-9-CM codes in the inpatient and outpatient
records for 2003 and were updated for each period. The
speciﬁc codes for identifying these conditions are listed in
Supplementary Table II (online only).
Diabetes duration was estimated as the number of years
a person had been treated for diabetes on October 1, 2003
in the VA healthcare system and was identiﬁed by searching
the VA inpatient and outpatient records from 1997, the
ﬁrst year these data sets are available for research. Hemo-
globin A1c and all cholesterol and blood pressure measures
were obtained at baseline and updated for each period. The
non-high-density lipoprotein cholesterol (non-HDL-C)
level was computed as the total cholesterol minus high-
density lipoprotein cholesterol (HDL-C). Non-HDL-C
levels have the advantage of being calculable in the
Fig 1. Kaplan-Meier survival curves for (A) lower extremity
amputation (LEA) and (B) treatment failure. This ﬁgure shows
Kaplan-Meier survival curves for three treatment groups (None,
Statin, and Other) over 5 years of follow-up for LEA and treat-
ment failure. None, No cholesterol-lowering medications; Other,
cholesterol-lowering medications other than statins; SE, standard
error; Statin, statins alone.
Fig 2. Cumulative incidence function curves for lower extremity
amputation (LEA) after adjusting for competing risks. This ﬁgure
shows cumulative incidence function curves for three treatment
groups (None, Statin, andOther) over 5 years of follow-up for LEA,
adjusting for death as a competing risk. None, No cholesterol-
lowering medications; Other, cholesterol-lowering medications
other than statins; Statin, statins alone.
JOURNAL OF VASCULAR SURGERY
1580 Sohn et al December 2013nonfasting state and include LDL-C. Moreover, in a large-
scale clinical trial of patients with diabetes, non-HDL-C
was shown to be a strong and independent predictor of
cardiovascular endpoints.8
We also obtained all height and weight measures taken
during visits to the VA hospitals or clinics in 2003 and in
each period. For all period-speciﬁc measures, when
a measure is not observed in a period, we used the last
observation carried forward method to impute the missing
values from the previous period, assuming that the lastobserved values did not change until the next measure-
ment.9 When multiple measures were available from the
same period, we used the average of all available values.
Statistical analysis. Our primary outcomes were
major LEAs and deaths identiﬁed during a 5-year follow-
up. Time to our primary outcomes were compared
between four groups of patients according to cholesterol-
lowering therapies they used: “nonusers” who were not
treated with any cholesterol-lowering medications, “statin
users” who were treated with statins alone, “nonstatin
users” who were treated with cholesterol-lowering medi-
cations other than statins, and “both users” who were
treated with both statins and nonstatin agents. We analyzed
the time to the ﬁrst major LEA using a competing risk
regression,10 adjusting for death as a competing risk. Time
to the ﬁrst LEA or death was analyzed using a Cox
regression. Both models included baseline patient charac-
teristics (age, race, marital status, diabetes duration >7
years at baseline) and time-varying covariates such as dia-
betes control (A1c), diabetic medication use, body mass
index (BMI), and comorbidities (CAD, PAD, foot ulcers,
osteomyelitis, diabetic neuropathy, and history of vascular
procedures) in each person-period. Patient gender was not
included in the ﬁnal regression models because it was not
signiﬁcant in both models, and a reliable estimate for LEA
risk was not available due to a small number of events for
females.
We graphically compared survival estimates by therapy
groups using Kaplan-Meier survival curves (Fig 1). The
number of patients at risk and standard errors of the esti-
mates at each major time point were provided below the
graphs. Note that none of the patients were taking any
cholesterol-lowering medications at baseline and so the
numbers for Year 0 are not provided. The curves for
both statin and nonstatin users were mainly overlapping
Table I. Baseline characteristics of the study cohort
Measures No. Mean (SD)
Percentiles
5% 25% Median 75% 95%
Age, years 83,593 52.3 (6.1) 40.0 49.0 54.0 57.0 59.0
Cholesterol levels, mg/dL
LDL-C 48,276 104.1 (34.1) 48.2 83.3 104.0 125.0 159.4
non-HDL-C 55,751 140.6 (38.4) 82.7 115.0 138.0 163.0 207.5
Total cholesterol 59,329 182.3 (40.0) 124.0 157.0 179.5 204.0 248.5
HDL-C 52,662 41.8 (14.5) 25.0 33.0 39.0 47.7 66.5
Triglycerides 52,783 200.4 (132.6) 80.0 114.0 162.0 241.7 447.0
Hemoglobin A1c, % 63,351 7.5 (1.8) 5.3 6.2 7.2 8.6 11.0
Blood pressure, mm Hg
Systolic 53,117 137.0 (15.5) 113.3 126.8 136.0 146.0 164.0
Diastolic 53,102 79.4 (9.0) 65.0 73.5 79.3 85.0 94.3
BMI, kg/m2 48,420 32.1 (6.8) 22.5 27.4 31.1 35.8 44.6
BMI, Body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SD, standard deviation.
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Kaplan-Meier curves are not appropriate in the presence
of competing risks,11 we also used the Cumulative Inci-
dence Function curves to compare cumulative risk of major
LEAs by four therapy groups, adjusting for deaths as
a competing risk (Fig 2). The sample provides power
>0.8 for a minimum detectable hazard ratio (HR) of
0.65 for LEAs and 0.95 for treatment failure between non-
users and statin users and of 0.41 for LEAs and 0.85 for
treatment failure between nonusers and nonstatin agent
users with alpha <.05 on a two-sided test. We use Stata/
SE 12.1 (StataCorp LP, College Station, Tex) for statistical
analysis. This study was approved by the institutional
review board at the Hines VA Hospital, Hines, Illinois.
RESULTS
There were 83,593 cholesterol drug-naïve individuals
in the study cohort, of whom 217 (0.3%) experienced
a major LEA and 11,716 (14.0%) experienced a treatment
failure during a mean follow-up of 4.6 years (median, 5
years).
Baseline characteristics are shown in Table I. Over half
of those who had valid measures consistently did not meet
ATP III goals12 recommended for persons with diabetes in
cholesterol levels (LDL-C $100 mg/dL, HDL-C <40
mg/dL), blood pressure ($130/80 mm Hg), and BMI
(BMI $30 kg/m2).
Patient characteristics in Table II show that about 75%
of the cohort were aged 50 years or older and 2.9% were 60
years or older at baseline. About 44% were non-Hispanic
white and 24% non-Hispanic black. Hemoglobin A1c was
measured for over 75% of the cohort in 2003, and 14%
of all patients (19% with A1c measures) had an average
A1c >9%. Twenty-one percent had diabetes for 7 years
or longer at baseline. Fourteen percent were treated with
insulin alone, 49% with oral medications alone, 13% with
both insulin and oral medications, and the rest (23%) did
not receive any pharmacological treatment for diabetes in
2003. Within this cohort, 11% had peripheral neuropathy,
10% CAD, 3% PAD, 0.12% history of vascular procedures,2% foot ulcers, 0.3% osteomyelitis, 1.6% renal failure, and
6% liver disease at baseline.
Compared with patients who have never experienced
an adverse outcome during follow-up, those who experi-
enced a treatment failure were older (52 vs 55 years),
had slightly higher A1c (7.50 vs 7.54 mg/dL), were less
likely to be obese (36.0% vs 27.4%), but were more likely
to have diabetes $7 years (19.7% vs 27.7%), CAD (8.5%
vs 18.0%), PAD (2.1% vs 6.0%), foot ulcers (1.5% vs
4.8%), and osteomyelitis (0.3% vs 0.6%) at baseline.
When we compared baseline characteristics of patients
between statin users and nonusers, we found that most
factors signiﬁcantly and positively associated with statin
use were also factors that are usually associated with poor
vascular health, including BMI >30 kg/m2 (30.5% for
nonusers vs 37.6% for statin users), A1c >9% (13.4% vs
15.3%), and PAD (2.4% vs 2.8%). However, at baseline,
more patients had foot ulcers (2.2% vs 1.8%), osteomyelitis
(0.18% vs 0.28%), and diabetes duration >7 years (21.4%
vs 20.6%) among nonusers than statin users.
Fig 1 shows Kaplan-Meier survival curves for LEA and
for the treatment failure by three therapy groups over 5
years. For LEAs, limb survival steadily decreased for both
nonuser (“None”) and statin (“Statin”) groups until the
4th year and leveled off during the last year of follow-up.
On the other hand, the nonstatin (“Other”) group experi-
enced most of the LEA events during the 3rd year. While
the nonstatin group had the best survival of the three
groups in these unadjusted Kaplan-Meier curves, the
cumulative incidence function curves from the full-
adjusted competing risk regression (Fig 2) shows that the
statin group had the lowest cumulative incidence and the
nonuser group had the highest cumulative incidence of
LEA, with the nonstatin group resembling the nonuser
group more than the statin group.
For the treatment failure, survival curves for the statin
and nonstatin groups mostly overlapped each other, but
they diverged from the nonuser group from the very begin-
ning of follow-up with an ever-widening gap in survival
throughout the entire follow-up.
Table II. Unadjusted rates of adverse outcomes by patient characteristics at baseline
LEA, No. (%) LEA or death, No. (%) No events, No. (%)
All 217 (100) 11,716 (100) 71,877 (100)
Age, years
<50 30 (13.8) 1805 (15.4) 19,626 (27.3)
50-54 60 (27.6) 3401 (29.0) 20,122 (28.0)
55-59 82 (37.8) 5566 (47.5) 30,642 (42.6)
60-64 41 (18.9) 944 (8.1) 1487 (2.1)
Gender
Female a 243 (2.1) 3412 (4.7)
Male a 11,473 (97.9) 68,465 (95.3)
Race/ethnicity
Non-Hispanic white 106 (48.8) 6341 (54.1) 30,333 (42.2)
Non-Hispanic black 75 (34.6) 3040 (25.9) 17,228 (24.0)
Other/unknown 36 (16.6) 2335 (19.9) 24,316 (33.8)
Marital status
Not married 134 (61.8) 7069 (60.3) 35,015 (48.7)
Married 83 (38.2) 4647 (39.7) 36,862 (51.3)
Hemoglobin A1c, %
<7 71 (32.7) 4005 (34.2) 25,033 (34.8)
7-9 50 (23.0) 3064 (26.2) 19,222 (26.7)
>9 58 (26.7) 1870 (16.0) 10,157 (14.1)
Unknown 38 (17.5) 2777 (23.7) 17,465 (24.3)
Diabetes duration, years
<7 121 (55.8) 8474 (72.3) 57,739 (80.3)
7 or longer 96 (44.2) 3242 (27.7) 14,138 (19.7)
BMI, kg/m2
<25 33 (15.2) 1564 (13.3) 4835 (6.7)
25-29.9 32 (14.7) 1596 (13.6) 10,947 (15.2)
30 or higher 43 (19.8) 3208 (27.4) 25,898 (36.0)
Unknown 109 (50.2) 5348 (45.6) 30,197 (42.0)
Antihyperglycemic medications
None 32 (14.7) 2133 (18.2) 17,280 (24.0)
Insulin alone 72 (33.2) 2719 (23.2) 8739 (12.2)
Oral medications alone 61 (28.1) 4498 (38.4) 36,982 (51.5)
Insulin and oral medications 52 (24.0) 2366 (20.2) 8876 (12.3)
Comorbidities
Peripheral neuropathy 79 (36.4) 1872 (16.0) 7048 (9.8)
CAD 54 (24.9) 2111 (18.0) 6144 (8.5)
PAD 57 (26.3) 705 (6.0) 1477 (2.1)
History of vascular procedure 12 (5.5) 54 (0.5) 47 (0.1)
Foot ulcers 98 (45.2) 565 (4.8) 1061 (1.5)
Osteomyelitis 16 (7.4) 51 (0.4) 138 (0.2)
Congestive heart failure 26 (12.0) 945 (8.1) 1090 (1.5)
Hypertension 142 (65.4) 6935 (59.2) 37,564 (52.3)
Paralysis 10 (4.6) 223 (1.9) 465 (0.6)
Chronic lung diseases 32 (14.7) 1663 (14.2) 5398 (7.5)
Renal failure 38 (17.5) 937 (8.0) 1143 (1.6)
Liver disease 20 (9.2) 1756 (15.0) 3287 (4.6)
BMI, Body mass index; CAD, coronary artery disease; LEA, lower extremity amputation;No events, no LEA or death during follow-up; PAD, peripheral artery
disease.
aCell with a small number.
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tions ﬁlled over the follow-up period for individuals with
LDL-C below and above 100 mg/dL. In this cholesterol
drug-naïve cohort at baseline, patients were not treated
with any cholesterol-lowering medications in 72% of all
periods during the 5-year follow-up. Patients were treated
with statins alone in 22% and by nonstatin medications
alone or statin and nonstatin medications together in 3%
and 2.7% of all periods, respectively. During periods
when patients were not treated with any cholesterol-
lowering medications, they had LDL-C $100 mg/dLfor 38.3% of periods. In 71% of periods, patients received
treatment consistent with ATP-III recommendations
(LDL-C <100 mg/dL or treated with statins). Altogether,
44.2% of all patients in the cohort have never been treated
with statins during follow-up. Among patients experi-
encing an LEA, only 32% were treated with statins, while
55.5% were treated with statins among those who did
not experience an amputation (data not shown).
Table IV lists HRs by type of cholesterol-lowering
therapy, adjusting for demographic factors, diabetes
severity, and other confounders. Compared with those
Table III. Distribution of the cohort by cholesterol-
lowering therapy and low-density lipoprotein cholesterol
(LDL-C) level, all periods (N ¼ 1,629,488)
Therapya % of all periodsb
LDL-C level during
period, % of therapy
<100 mg/dL $100 mg/dL
None 71.9 61.8 38.3
Statin 22.3 59.7 40.3
Nonstatin 3.0 55.1 44.9
Both 2.7 63.9 36.1
All patients 100 61.1 36.1
aBoth, Used both statins and nonstatin classes of cholesterol-lowering
medications; Nonstatin, used nonstatin classes of cholesterol-lowering
medications alone; None, prescribed no cholesterol-lowering medications;
Statin, used statins alone.
bDo not sum up to 100% due to rounding errors.
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of statins alone were about 35% less likely to experience
any LEA (HR, 0.65; 95% conﬁdence interval [CI], 0.42-
0.99; P ¼ .045) and 43% less likely to experience a treat-
ment failure (HR, 0.57; 95% CI, 0.54-0.60; P < .001).
The LEA risk for nonstatin users was not signiﬁcantly
different (HR, 0.95; 95% CI, 0.35-2.60; P ¼ .915) from
that for nonusers, but they were 41% less likely to experi-
ence a treatment failure (HR, 0.59; 95% CI, 0.51-0.68;
P < .001) than nonusers. Individuals on both statin and
nonstatin agents were 50% less likely to experience a treat-
ment failure (HR, 0.51; 95% CI, 0.43-0.59; P < .001).DISCUSSION
Our results show that 0.3% of nonelderly patients with
diabetes who did not use any cholesterol-lowering medica-
tions at baseline had a major amputation in the lower
extremities, and 14% died during a 5-year follow-up.
Within this cohort, patients who used statins had a 35%
lower risk of an LEA, compared with those who were
not treated with any cholesterol-lowering medications.
The use of other classes of medications appears to be mini-
mally, if at all, associated with lower risk of LEA, but our
sample was not adequately powered to test statistical signif-
icance of this association. On the other hand, the use of
any cholesterol-lowering medications (statins, nonstatin
medications, or both) was associated with increased
amputation-free survival over 5 years. These results imply
that statin use may be associated with a decrease in ampu-
tation risk, but the use of nonstatin agents may not share in
this protection against limb loss.
Since their introduction, statins have been used not
only for LDL-C reduction but for improvement in survival
in patients at high risk for cardiovascular events. Random-
ized controlled trials such as the Heart Protection Study,13
Collaborative Atorvastatin Diabetes Study,14 and Scan-
dinavian Simvastatin Survival Study (4S)15 provide strong
clinical evidence that statin therapy is associated witha reduction in mortality both for primary and secondary
prevention, particularly in patients with diabetes.
Statins have also been shown to modify disease burden
and morbidity in patients with lower extremity occlusive
disease. In the Regression Growth Evaluation Statin Study
(REGRESS), pravastatin use was associated with decrease
in atherosclerotic plaque burden, as assessed by ultrasound
of the femoral artery.16 In small cohorts, statin therapy has
been demonstrated to increase walking time and distance17
and delay functional decline.18 The 4S study was the ﬁrst
randomized controlled trial to demonstrate an improve-
ment in PAD symptoms. In the 153 subjects with PAD,
simvastatin was associated with a 38% reduction in new
or worsening intermittent claudication.19 In patients with
diabetes, peripheral neuropathy is an independent risk
factor for LEA and increases the risk for foot ulcers and
LEA multiplicatively in the presence of PAD.20 Previous
research has shown that statins are associated with
improvement in microvascular function and peripheral
neuropathy, independent of LDL-C lowering.21 Despite
accumulating evidence that statins have these beneﬁcial
effects on vascular health, clinical research until now has
not clearly demonstrated beneﬁcial effects of statins on
amputation risk.22
Some propose that in addition to the proven beneﬁts of
LDL-C lowering on atherosclerotic cardiovascular disease
(ASCVD) risk, pleiotropic effects of statins may explain
other favorable results. In the Justiﬁcation for the Use of
Statins in Primary Prevention study, a primary prevention
clinical trial, investigators showed beneﬁt of those men
$50 and women $ 60 years, both with high-sensitivity
C-reactive protein >2 mg/L, randomized to rosuvastatin
20 mg/day as contrasted with placebo as regards the
combined primary endpoint of ASCVD outcomes.23 While
this result is explained by the statin effects on lowering
LDL-C levels, the 43% reduction in the risk of venous
thromboembolism in those randomized to rosuvastatin in
this trial is less convincingly assumed to be related to
statin-induced LDL-C reduction.24
The role of nonstatin cholesterol-lowering medications
in the maintenance of diabetic limb health is unclear. In our
cohort, nonstatin cholesterol-lowering medications were
associated with a nonsigniﬁcant decrease in amputation
and a less robust, but signiﬁcant, reduction in treatment
failure. In comparison, the Fenoﬁbrate Intervention and
Event Lowering in Diabetes (FIELD) trial evaluated the
use of fenoﬁbrate as monotherapy in 9795 subjects with
type 2 diabetes.25 Fenoﬁbrate did not signiﬁcantly reduce
the risk of the primary outcome of coronary events or total
mortality. It did reduce total cardiovascular events, mainly
due to fewer nonfatal myocardial infarctions and revascular-
izations. Over the 5 years of follow-up, there was a signiﬁ-
cantly lower rate of minor amputations in the fenoﬁbrate
treated group but no signiﬁcant difference in major ampu-
tations.26 The beneﬁt of fenoﬁbrate to prevent minor
amputation was strongest in subjects with known microvas-
cular disease such as retinopathy and microalbuminuria.
There was no strong association between amputation and
Table IV. Hazard ratios (HRs) and their 95% conﬁdence intervals (CIs) of any lower-extremity amputation (LEA) or any
LEA or death for users of different cholesterol-lowering medications compared with nonusers
LEA LEA or death
HR (95% CI)a P value HR (95% CI) P value
Statin 0.645 (0.420-0.991) .045 0.569 (0.537-0.602) <.001
Nonstatin 0.946 (0.345-2.596) .915 0.586 (0.508-0.676) <.001
Bothb e e 0.505 (0.433-0.589) <.001
BMI, Body mass index; CAD, coronary artery disease; PAD, peripheral arterial disease.
Both models were adjusted for age, race/ethnicity, marital status, A1c, BMI, insulin use and/or oral antihyperglycemic medication use, history of vascular
surgery, and comorbidities (foot ulcer, CAD, PAD, peripheral neuropathy, foot ulcers, and osteomyelitis). The LEA model was additionally adjusted for
mortality as a competing risk.
aHRs for LEA were adjusted for deaths as competing risks.
bFor LEA, a reliable estimate was not available for the “Both” group due to small number of events (n ¼ 7).
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cohort were treated with nonstatin agents for only 6% of all
periods (3% with nonstatin agents alone and 2.7% with sta-
tins and nonstatins together) and, as such, our ability to
draw inferences about users of nonstatin agents may be
limited. Both our study and the FIELD study highlighted
the unique pathology of the microvasculature in diabetes.
One must recognize the limitations inherent in the
inclusion/exclusion criteria for this cohort study that may
limit its broad generalizability. The study population is
entirely persons with diabetes, disproportionately male,
and limited to those who are nonelderly. It remains unclear
if a similar beneﬁt of statins is attributable to individuals with
different characteristics. Given that this is a retrospective
study, we were required to assume that statin prescriptions
ﬁlled during each period implied actual use. We also could
not entirely exclude the possibility that some statins were
ﬁlled outside the VA and were not accounted for in our
analysis. Finally, as in other retrospective studies, it was
impossible for us to exclude all sources of confounding,
especially one due to patient selection. When we compared
baseline characteristics of patients between nonusers and
statin users, we found that statin users did not necessarily
have better vascular health at baseline than nonusers to
the extent that patient selection alone could have explained
the differences in event rates between our comparison
groups. It is noteworthy that the rate of statin use in our
cohort is surprisingly low. Even though we did not have
information on contraindications to safe statin use, such as
allergies and adverse side effects, it is worrisome that
patients in our study cohort did not meet the LDL-C target
(<100 mg/dL) for 36.1% of all periods during follow-up
but were not treated with any cholesterol-lowering medi-
cation in 70.8% of these periods (Table III). Patients in
general were treated with statins for 25% of all periods
(22.3% with statins alone and 2.7% with both statins and
other agents). Limited statin use in our cohort is not an
exception, however. Under-utilization of statins and subop-
timal LDL-C levels have been documented in other diabetic
populations as well.27 While this study supports a positive
relationship between statin use and limb survival, our abilityto draw an inference about the positive effect of statins on
the micro- and macrovasculature is limited. Unfortunately,
our clinical cohort remains incompletely characterized. In
the literature, one-third of patients with diabetes have
concomitant PAD.28 Our cohort has a low reported rate
of PAD (3% at baseline), which likely reﬂects broad under-
diagnosis. Because ankle-brachial index measures were not
available for use in this study, we could not verify accuracy
of PAD based on the ICD-9-CM diagnostic coding in inpa-
tient and outpatient administrative records.
In conclusion, this is the ﬁrst study that demonstrated
protective effects of statins in LEA. Even though we
limited our sample to nonelderly diabetic patients, our
large sample from observational data allowed us to observe
a striking effect of statin therapy on LEA risk and
amputation-free survival. Finally, we showed that there
were a large number of patients with diabetes who were
not treated for cholesterol lowering. These ﬁndings indi-
cate an area where clinical practice may need improvement,
and at the same time, offer an opportunity for a future
study. While prospective clinical trial data support wide-
spread use of statins in those with diabetes and ASCVD,5
it is not known if statin therapy that titrates to ATP-III
goal is superior to just initiating ﬁxed-dose statin therapy
in this high-risk population. A clinical trial that randomized
those with diabetes and ASCVD to either an intensive
treatment arm (using a maximally tolerated statin dosage
to achieve an LDL-C <70 mg/dL) or merely a ﬁxed
moderate dose arm (such as simvastatin 40 mg/day or
atorvastatin 10 mg/day) has the promise to provide useful
information for the care of these patients. Given that
moderate dose statins in the Collaborative Atorvastatin
Diabetes Study (CARDS) trial had a beneﬁcial effect on
CVD outcomes, it is important to know if using high-
dose potent statins with their attendant increase in statin-
related side effects and possibly decreased adherence is
worth the increased cost and effort.
The paper presents the ﬁndings and conclusions of
the authors; it does not necessarily represent the Depart-
ment of Veterans Affairs, Health Services Research and
Development Service, or the National Institutes of Health.
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Supplementary Table I (online only). Procedure codes
used to identify major amputations
Level ICD-9-CM codes CPT-4 codes
Ankle or leg 84.13 e 84.15 27880 e 27889
Knee or above 84.16 e 84.17 27590 e 27598
CPT, Current Procedural Terminology, Version 4; ICD-9-CM, Interna-
tional Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation.
Supplementary Table II (online only). Comorbidities and their deﬁnitions in International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) codes
Coexisting condition ICD-9-CM codes
Peripheral neuropathy 250.6, 355.x, 337.1, 357.2
CAD 410.xx-414.xx, 429.2
PAD 250.7, 443.9
History of vascular procedure Procedure codes 39.25, 39.29, 39.49, 39.50, 39.90, or
00.40-00.48, 00.55, 00.60 used with 440.20-440.24 diagnostic codes
Foot ulcers 707.1x, 707.9
Osteomyelitis 730.06-730.09, 731.06-731.09, 732.06-732.09
CAD, Coronary artery disease; PAD, peripheral artery disease.
Diagnostic codes for all other comorbidities were obtained from http://www.hcup-us.ahrq.gov/reports/ComorbiditySoftwareDocumentationFinal.pdf.
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